Explore Business Standard
Biocon
Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .
Biocon Chairperson Kiran Mazumdar-Shaw on Friday said the convergence of biological intelligence and artificial intelligence (AI) can drive a paradigm shift in medicine, enabling breakthroughs in predictive healthcare, regenerative science and lifespan management. "Biology on its own was limited in generating deeper insights, but AI tools are opening immeasurable opportunities to understand living systems," Mazumdar-Shaw said while speaking at the AI Impact Summit here. She noted that biological systems function like distributed data centres, processing information with minimal energy compared to gigawatt-powered AI systems. "Biology has a lot to teach AI in terms of how to do it with less energy, how to do it rapidly, and how to multiplex multimodal data very quickly," she said. Mazumdar-Shaw described reprogramming cells - such as converting malignant cancer cells into non-malignant ones - as the 'holy grail' of medicine. She said AI could accelerate regenerative science and hel
Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon